Related Experiment Videos
BMS-214662 (Bristol-Myers Squibb)
1Department of Medicine (Breast Unit), Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK. stephen@icr.ac.uk
Idrugs : the Investigational Drugs Journal
|June 6, 2003
Summary
Bristol-Myers Squibb is investigating BMS-214662, a farnesyl transferase inhibitor, as a potential cancer treatment. Clinical trials are underway in the US for various cancers, including pancreatic and lung.
Area of Science:
- Oncology
- Pharmacology
Background:
- Bristol-Myers Squibb is developing BMS-214662.
- BMS-214662 is a farnesyl transferase inhibitor.
Purpose of the Study:
- To evaluate the potential of BMS-214662 in cancer treatment.
Main Methods:
- Preclinical investigations were conducted in Japan.
- Phase II clinical trials initiated in the US.
Main Results:
- BMS-214662 is under investigation for multiple cancer types.
Conclusions:
- BMS-214662 shows potential as a novel cancer therapeutic agent.